Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): A new biomarker for lung cancer

Neoplasma

Volumn 57, Issue 1, 2010, Pages 55-61

  Jing, R ^a   Cui, M ^a   Wang, J ^a   Wang, H ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Lung cancer; RAGE; Serum; sRAGE; Tissue

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; BLOOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77953638811     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_01_055     Document Type: Article

References (29)

1. PARKIN DM, BRAY F, FERLAY J, PISANI P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. doi:10.3322/canjclin.55.2.74
2. MOUNTAIN CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717. doi:10.1378/chest.111.6.1710
3. VLASSARA H, BUCALA R, STRIKER L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-151.
4. BROWNLEE M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234. doi:10.1146/ annurev.med.46.1.223
5. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem1991; 266: 11654-11660.
6. GRANDHEE SK, MONNIER VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem1991; 266: 11649-11653.
7. THORNALLEY PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1013-1023.
8. SCHMIDT AM, STERN DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000; 11: 368-375. doi:10.1016/S1043-2760(00)00311-8
9. SCHMIDT AM, VIANNA M, GERLACH M, BRETT J, RYAN J et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
10. NEEPER M, SCHMIDT AM, BRETT J, YAN SD, WANG F et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
11. SINGH R, BARDEN A, MORI T, BEILIN L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. doi:10.1007/s001250051591
12. JING RR, WANG HM, JIANG SY, ZHANG ZQ. Up regulation of RAGE in esophageal cancer and down regulation in lung cancer and their relationship to clinicopathological features. Labmedicine 2008; 39: 661-667.
13. KUNIYASU H, CHIHARA Y, TAKAHASHI T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 445-448.
14. SASAHIRA T, KIRITA T, BHAWAL UK, YAMAMOTO K, OHMORI H et al. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 2007; 51: 166-172. doi:10.1111/j.1365-2559.2007.02739.x
15. BARTLING B, HOFMANN HS, WEIGLE B, SILBER RE, SIMM A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005; 26: 293-301. doi:10.1093/ carcin/bgh333
16. PARK IH, YEON SI, YOUN JH, CHOI JE, SASAKI N. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004; 40: 1203-1211. doi:10.1016/j.molimm.2003.11.027
17. TESAROVÁ P, KALOUSOVÁ M, JÁCHYMOVÁ M, MESTEK O, PETRUZELKA L. Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007; 25: 720-725. doi:10.1080/07357900701560521
18. NAKAMURA K, YAMAGISHI S, ADACHI H, KURITA-NAKAMURA Y, MATSUI T et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13: 185-189. doi:10.2119/2006-00090.Nakamura
19. NAKAMURA K, YAMAGISHI S, NAKAMURA Y, TAKENAKA K, MATSUI T et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70: 137-141. doi:10.1016/ j.mvr.2005.10.002
20. ALLRED DC, HARVEY JM, BERARDO M, CLARK GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
21. KUMURA T, HINO M, YAMANE T, TOMINAGA K, TATSUMI N. DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes. Clin Chim Acta 2000; 294: 27-35. doi:10.1016/S0009-8981(00)00185-6
22. LIZOTTE PP, HANFORD LE, ENGHILD JJ, NOZIKGRAYCK E, GILES BL et al. Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung. BMC Dev Biol 2007; 7: 15. doi:10.1186/1471-213X-7-15
23. STERENCZAK KA, WILLENBROCK S, BARANN M. Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 2009; 434: 35-42. doi:10.1016/j.gene.2008.10.027
24. HUTTUNEN HJ, RAUVALA H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 2004; 255: 351-366. doi:10.1111/j.1365-2796.2003.01301.x
25. ROTH J, VOGL T, SORG C, SUNDERKÖTTER C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 155-158. doi:10.1016/ S1471-4906(03)00062-0
26. TAGUCHI A, BLOOD DC, DEL TORO G, CANET A, LEE DC et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360. doi:10.1038/35012626
27. RIUZZI F, SORCI G, DONATO R. The amphoterin (HMGB1)/ receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 2006; 281:8242-8253. doi:10.1074/jbc.M509436200
28. STEINER M, REINHARDT KM, KRAMMER B, ERNST B, BLANN AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994; 72: 979-984.
29. PACHYDAKI SI, TARI SR, LEE SE, MA W, TSENG JJ et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006; 82: 807-815. doi:10.1016/ j.exer.2005.09.022